Effect of posttranslational processing on the in vitro and in vivo activity of chemokines

Experimental Cell Research

Volumn 317, Issue 5, 2011, Pages 642-654

  Mortier, Anneleen ^a   Gouwy, Mieke ^a   Van Damme, Jo ^a   Proost, Paul ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Chemokine; Glycosylation; Peptidylarginine deiminase; Posttranslational modification; Protease

Indexed keywords

CCL14 CHEMOKINE; CCL15 CHEMOKINE; CCL23 CHEMOKINE; CCL3L1 CHEMOKINE; CHEMOKINE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL4 CHEMOKINE; CXCL7 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; REVIEW;

EID: 79952102426     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.11.016     Document Type: Review

References (155)

1. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
2. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
3. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., Power C.A. International union of pharmacology: XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52:145-176.
4. Murphy P.M. International Union of Pharmacology: XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 2002, 54:227-229.
5. Nomiyama H., Osada N., Yoshie O. The evolution of mammalian chemokine genes. Cytokine Growth Factor Rev. 2010, 21:253-262.
6. Menten P., Wuyts A., Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 2002, 13:455-481.
7. Van Coillie E., Van Damme J., Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999, 10:61-86.
8. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
9. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., Kakizaki M., Takagi S., Nomiyama H., Schall T.J., Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.
10. Shimaoka T., Nakayama T., Fukumoto N., Kume N., Takahashi S., Yamaguchi J., Minami M., Hayashida K., Kita T., Ohsumi J., Yoshie O., Yonehara S. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J. Leukoc. Biol. 2004, 75:267-274.
11. Matloubian M., David A., Engel S., Ryan J.E., Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 2000, 1:298-304.
12. Fong A.M., Robinson L.A., Steeber D.A., Tedder T.F., Yoshie O., Imai T., Patel D.D. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 1998, 188:1413-1419.
13. Ludwig A., Mentlein R. Glial cross-talk by transmembrane chemokines CX3CL1 and CXCL16. J. Neuroimmunol. 2008, 198:92-97.
14. Prinz M., Priller J. Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS. J. Neuroimmunol. 2010, 224:80-84.
15. Kelner G.S., Kennedy J., Bacon K.B., Kleyensteuber S., Largaespada D.A., Jenkins N.A., Copeland N.G., Bazan J.F., Moore K.W., Schall T.J. Lymphotactin: a cytokine that represents a new class of chemokine. Science 1994, 266:1395-1399.
16. Crozat K., Guiton R., Contreras V., Feuillet V., Dutertre C.A., Ventre E., Vu Manh T.P., Baranek T., Storset A.K., Marvel J., Boudinot P., Hosmalin A., Schwartz-Cornil I., Dalod M. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+dendritic cells. J. Exp. Med. 2010, 207:1283-1292.
17. Bachem A., Guttler S., Hartung E., Ebstein F., Schaefer M., Tannert A., Salama A., Movassaghi K., Opitz C., Mages H.W., Henn V., Kloetzel P.M., Gurka S., Kroczek R.A. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 2010, 207:1273-1281.
18. Dorner B.G., Dorner M.B., Zhou X., Opitz C., Mora A., Guttler S., Hutloff A., Mages H.W., Ranke K., Schaefer M., Jack R.S., Henn V., Kroczek R.A. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity 2009, 31:823-833.
19. Strieter R.M., Burdick M.D., Gomperts B.N., Belperio J.A., Keane M.P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:593-609.
20. Murphy P.M. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat. Immunol. 2001, 2:116-122.
21. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
22. Struyf S., Burdick M.D., Peeters E., Van den Broeck K., Dillen C., Proost P., Van Damme J., Strieter R.M. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007, 67:5940-5948.
23. Koenen R.R., Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat. Rev. Drug Discov. 2010, 9:141-153.
24. Proudfoot A.E., Power C.A., Schwarz M.K. Anti-chemokine small molecule drugs: a promising future?. Expert Opin. Investig. Drugs 2010, 19:345-355.
25. Walters M.J., Wang Y., Lai N., Baumgart T., Zhao B.N., Dairaghi D.J., Bekker P., Ertl L.S., Penfold M.E., Jaen J.C., Keshav S., Wendt E., Pennell A., Ungashe S., Wei Z., Wright J.J., Schall T.J. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 2010, 335:61-69.
26. Gouwy M., Struyf S., Proost P., Van Damme J. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev. 2005, 16:561-580.
27. Proost P., Vynckier A.K., Mahieu F., Put W., Grillet B., Struyf S., Wuyts A., Opdenakker G., Van Damme J. Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur. J. Immunol. 2003, 33:3146-3153.
28. Wuyts A., Struyf S., Gijsbers K., Schutyser E., Put W., Conings R., Lenaerts J.P., Geboes K., Opdenakker G., Menten P., Proost P., Van Damme J. The CXC chemokine GCP-2/CXCL6 is predominantly induced in mesenchymal cells by interleukin-1beta and is down-regulated by interferon-gamma: comparison with interleukin-8/CXCL8. Lab Invest. 2003, 83:23-34.
29. Johnson Z., Proudfoot A.E., Handel T.M. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 2005, 16:625-636.
30. Rot A. Chemokine patterning by glycosaminoglycans and interceptors. Front. Biosci. 2010, 15:645-660.
31. Mantovani A., Bonecchi R., Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 2006, 6:907-918.
32. Venetz D., Ponzoni M., Schiraldi M., Ferreri A.J., Bertoni F., Doglioni C., Uguccioni M. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int. J. Cancer 2010, 127:2300-2312.
33. Gouwy M., Struyf S., Noppen S., Schutyser E., Springael J.Y., Parmentier M., Proost P., Van Damme J. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol. Pharmacol. 2008, 74:485-495.
34. Broxmeyer H.E., Sherry B., Cooper S., Lu L., Maze R., Beckmann M.P., Cerami A., Ralph P. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J. Immunol. 1993, 150:3448-3458.
35. Broxmeyer H.E., Pelus L.M., Kim C.H., Hangoc G., Cooper S., Hromas R. Synergistic inhibition in vivo of bone marrow myeloid progenitors by myelosuppressive chemokines and chemokine-accelerated recovery of progenitors after treatment of mice with Ara-C. Exp. Hematol. 2006, 34:1069-1077.
36. Colobran R., Pedrosa E., Carretero-Iglesia L., Juan M. Copy number variation in chemokine superfamily: the complex scene of CCL3L-CCL4L genes in health and disease. Clin. Exp. Immunol. 2010, 162:41-52.
37. Eisman R., Surrey S., Ramachandran B., Schwartz E., Poncz M. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 1990, 76:336-344.
38. Green C.J., Charles R.S., Edwards B.F., Johnson P.H. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol. Cell. Biol. 1989, 9:1445-1451.
39. Menten P., Struyf S., Schutyser E., Wuyts A., De Clercq E., Schols D., Proost P., Van Damme J. The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J. Clin. Invest. 1999, 104:R1-R5.
40. Nibbs R.J., Yang J., Landau N.R., Mao J.H., Graham G.J. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J. Biol. Chem. 1999, 274:17478-17483.
41. Gonzalez E., Kulkarni H., Bolivar H., Mangano A., Sanchez R., Catano G., Nibbs R.J., Freedman B.I., Quinones M.P., Bamshad M.J., Murthy K.K., Rovin B.H., Bradley W., Clark R.A., Anderson S.A., O'connell R.J., Agan B.K., Ahuja S.S., Bologna R., Sen L., Dolan M.J., Ahuja S.K. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005, 307:1434-1440.
42. Struyf S., Burdick M.D., Proost P., Van Damme J., Strieter R.M. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ. Res. 2004, 95:855-857.
43. Graham G.J. D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur. J. Immunol. 2009, 39:342-351.
44. Rot A. Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev. 2005, 16:687-694.
45. Savino B., Borroni E.M., Torres N.M., Proost P., Struyf S., Mortier A., Mantovani A., Locati M., Bonecchi R. Recognition versus adaptive up-regulation and degradation of CC chemokines by the chemokine decoy receptor D6 are determined by their N-terminal sequence. J. Biol. Chem. 2009, 284:26207-26215.
46. Mortier A., Van Damme J., Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol. Ther. 2008, 120:197-217.
47. Schröder J.M., Sticherling M., Henneicke H.H., Preissner W.C., Christophers E. IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. J. Immunol. 1990, 144:2223-2232.
48. Yoshimura T., Robinson E.A., Appella E., Matsushima K., Showalter S.D., Skeel A., Leonard E.J. Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF) distinguished by different lengths of the amino-terminal sequence. Mol. Immunol. 1989, 26:87-93.
49. Furutani Y., Nomura H., Notake M., Oyamada Y., Fukui T., Yamada M., Larsen C.G., Oppenheim J.J., Matsushima K. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem. Biophys. Res. Commun. 1989, 159:249-255.
50. Jiang Y., Tabak L.A., Valente A.J., Graves D.T. Initial characterization of the carbohydrate structure of MCP-1. Biochem. Biophys. Res. Commun. 1991, 178:1400-1404.
51. Robinson E.A., Yoshimura T., Leonard E.J., Tanaka S., Griffin P.R., Shabanowitz J., Hunt D.F., Appella E. Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions. Proc. Natl Acad. Sci. USA 1989, 86:1850-1854.
52. Van Damme J., Van Beeumen J., Conings R., Decock B., Billiau A. Purification of granulocyte chemotactic peptide/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of beta-thromboglobulin. Eur. J. Biochem. 1989, 181:337-344.
53. Loos T., Mortier A., Gouwy M., Ronsse I., Put W., Lenaerts J.P., Van Damme J., Proost P. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 2008, 112:2648-2656.
54. Proost P., Loos T., Mortier A., Schutyser E., Gouwy M., Noppen S., Dillen C., Ronsse I., Conings R., Struyf S., Opdenakker G., Maudgal P.C., Van Damme J. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J. Exp. Med. 2008, 205:2085-2097.
55. Van Coillie E., Proost P., Van Aelst I., Struyf S., Polfliet M., De Meester I., Harvey D.J., Van Damme J., Opdenakker G. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 1998, 37:12672-12680.
56. Gimbrone M.A., Obin M.S., Brock A.F., Luis E.A., Hass P.E., Hebert C.A., Yip Y.K., Leung D.W., Lowe D.G., Kohr W.J. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science 1989, 246:1601-1603.
57. Hebert C.A., Luscinskas F.W., Kiely J.M., Luis E.A., Darbonne W.C., Bennett G.L., Liu C.C., Obin M.S., Gimbrone M.A., Baker J.B. Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils. J. Immunol. 1990, 145:3033-3040.
58. Nakagawa H., Hatakeyama S., Ikesue A., Miyai H. Generation of interleukin-8 by plasmin from AVLPR-interleukin-8, the human fibroblast-derived neutrophil chemotactic factor. FEBS Lett. 1991, 282:412-414.
59. Ohashi K., Naruto M., Nakaki T., Sano E. Identification of interleukin-8 converting enzyme as cathepsin L. Biochim. Biophys. Acta 2003, 1649:30-39.
60. Padrines M., Wolf M., Walz A., Baggiolini M. Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. FEBS Lett. 1994, 352:231-235.
61. Proost P., Mortier A., Loos T., Vandercappellen J., Gouwy M., Ronsse I., Schutyser E., Put W., Parmentier M., Struyf S., Van Damme J. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007, 110:37-44.
62. Tester A.M., Cox J.H., Connor A.R., Starr A.E., Dean R.A., Puente X.S., Lopez-Otin C., Overall C.M. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS ONE 2007, 2:e312.
63. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96:2673-2681.
64. Ehlert J.E., Petersen F., Kubbutat M.H., Gerdes J., Flad H.D., Brandt E. Limited and defined truncation at the C terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2). Comparison of native and recombinant NAP-2 variants. J. Biol. Chem. 1995, 270:6338-6344.
65. Ehlert J.E., Gerdes J., Flad H.D., Brandt E. Novel C-terminally truncated isoforms of the CXC chemokine beta-thromboglobulin and their impact on neutrophil functions. J. Immunol. 1998, 161:4975-4982.
66. Proost P., De Wolf-Peeters C., Conings R., Opdenakker G., Billiau A., Van Damme J. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J. Immunol. 1993, 150:1000-1010.
67. Van Osselaer N., Van Damme J., Rampart M., Herman A.G. Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin. Am. J. Pathol. 1991, 138:23-27.
68. Mortier A., Loos T., Gouwy M., Ronsse I., Van Damme J., Proost P. Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity. J. Biol. Chem. 2010, 285:29750-29759.
69. Bryan J.D., Shelver D.W. Streptococcus agalactiae CspA is a serine protease that inactivates chemokines. J. Bacteriol. 2009, 191:1847-1854.
70. Zinkernagel A.S., Timmer A.M., Pence M.A., Locke J.B., Buchanan J.T., Turner C.E., Mishalian I., Sriskandan S., Hanski E., Nizet V. The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe 2008, 4:170-178.
71. Kurupati P., Turner C.E., Tziona I., Lawrenson R.A., Alam F.M., Nohadani M., Stamp G.W., Zinkernagel A.S., Nizet V., Edwards R.J., Sriskandan S. Chemokine-cleaving Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract. Mol. Microbiol. 2010, 76:1387-1397.
72. Proost P., Schutyser E., Menten P., Struyf S., Wuyts A., Opdenakker G., Detheux M., Parmentier M., Durinx C., Lambeir A.M., Neyts J., Liekens S., Maudgal P.C., Billiau A., Van Damme J. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001, 98:3554-3561.
73. Hensbergen P.J., Verzijl D., Balog C.I., Dijkman R., Van Der Schors R.C., Van Der Raaij-Helmer E.M., van der Plas M.J., Leurs R., Deelder A.M., Smit M.J., Tensen C.P. Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity. J. Biol. Chem. 2004, 279:13402-13411.
74. Proost P., Struyf S., Loos T., Gouwy M., Schutyser E., Conings R., Ronsse I., Parmentier M., Grillet B., Opdenakker G., Balzarini J., Van Damme J. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res. Ther. 2006, 8:R107.
75. Broxmeyer H.E. Chemokines in hematopoiesis. Curr. Opin. Hematol. 2008, 15:49-58.
76. Cho S.Y., Xu M., Roboz J., Lu M., Mascarenhas J., Hoffman R. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res. 2010, 70:3402-3410.
77. McQuibban G.A., Butler G.S., Gong J.H., Bendall L., Power C., Clark-Lewis I., Overall C.M. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 2001, 276:43503-43508.
78. Davis D.A., Singer K.E., De La Luz S.M., Narazaki M., Yang F., Fales H.M., Yarchoan R., Tosato G. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 2005, 105:4561-4568.
79. Proost P., Struyf S., Schols D., Durinx C., Wuyts A., Lenaerts J.P., De Clercq E., De Meester I., Van Damme J. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett. 1998, 432:73-76.
80. Delgado M.B., Clark-Lewis I., Loetscher P., Langen H., Thelen M., Baggiolini M., Wolf M. Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur. J. Immunol. 2001, 31:699-707.
81. Staudt N.D., Aicher W.K., Kalbacher H., Stevanovic S., Carmona A.K., Bogyo M., Klein G. Cathepsin X is secreted by human osteoblasts, digests CXCL-12 and impairs adhesion of hematopoietic stem and progenitor cells to osteoblasts. Haematologica 2010, 95:1452-1460.
82. Christopherson K.W., Cooper S., Broxmeyer H.E. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 2003, 101:4680-4686.
83. Christopherson K.W., Cooper S., Hangoc G., Broxmeyer H.E. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp. Hematol. 2003, 31:1126-1134.
84. Jin F., Zhai Q., Qiu L., Meng H., Zou D., Wang Y., Li Q., Yu Z., Han J., Li Q., Zhou B. Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant. 2008, 42:581-588.
85. Levesque J.P., Hendy J., Takamatsu Y., Simmons P.J., Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest. 2003, 111:187-196.
86. Petit I., Szyper-Kravitz M., Nagler A., Lahav M., Peled A., Habler L., Ponomaryov T., Taichman R.S., Arenzana-Seisdedos F., Fujii N., Sandbank J., Zipori D., Lapidot T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 2002, 3:687-694.
87. Christopherson K.W., Hangoc G., Mantel C.R., Broxmeyer H.E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004, 305:1000-1003.
88. Narducci M.G., Scala E., Bresin A., Caprini E., Picchio M.C., Remotti D., Ragone G., Nasorri F., Frontani M., Arcelli D., Volinia S., Lombardo G.A., Baliva G., Napolitano M., Russo G. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 2006, 107:1108-1115.
89. Sun Y.X., Pedersen E.A., Shiozawa Y., Havens A.M., Jung Y., Wang J., Pienta K.J., Taichman R.S. CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin. Exp. Metastasis 2008, 25:765-776.
90. Decock B., Conings R., Lenaerts J.P., Billiau A., Van Damme J. Identification of the monocyte chemotactic protein from human osteosarcoma cells and monocytes: detection of a novel N-terminally processed form. Biochem. Biophys. Res. Commun. 1990, 167:904-909.
91. Proost P., Struyf S., Couvreur M., Lenaerts J.P., Conings R., Menten P., Verhaert P., Wuyts A., Van Damme J. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J. Immunol. 1998, 160:4034-4041.
92. McQuibban G.A., Gong J.H., Wong J.P., Wallace J.L., Clark-Lewis I., Overall C.M. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002, 100:1160-1167.
93. Denney H., Clench M.R., Woodroofe M.N. Cleavage of chemokines CCL2 and CXCL10 by matrix metalloproteinases-2 and -9: implications for chemotaxis. Biochem. Biophys. Res. Commun. 2009, 382:341-347.
94. McQuibban G.A., Gong J.H., Tam E.M., McCulloch C.A., Clark-Lewis I., Overall C.M. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000, 289:1202-1206.
95. Pertuz B.S., Ostoa S.P., Benitez I., Soldevila G., Olivos A., Garcia-Zepeda E. Entamoeba histolytica cysteine protease 2 (EhCP2) modulates leucocyte migration by proteolytic cleavage of chemokines. Parasite Immunol. 2004, 26:237-241.
96. Noso N., Bartels J., Mallet A.I., Mochizuki M., Christophers E., Schröder J.M. Delayed production of biologically active O-glycosylated forms of human eotaxin by tumor-necrosis-factor-alpha-stimulated dermal fibroblasts. Eur. J. Biochem. 1998, 253:114-122.
97. Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., Boykins R., Unsworth E., Norcross M.A. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 1997, 186:1865-1872.
98. Struyf S., Proost P., Schols D., De Clercq E., Opdenakker G., Lenaerts J.P., Detheux M., Parmentier M., De Meester I., Scharpé S., Van Damme J. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J. Immunol. 1999, 162:4903-4909.
99. Forssmann U., Stoetzer C., Stephan M., Kruschinski C., Skripuletz T., Schade J., Schmiedl A., Pabst R., Wagner L., Hoffmann T., Kehlen A., Escher S.E., Forssmann W.G., Elsner J., von Horsten S. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J. Immunol. 2008, 181:1120-1127.
100. Culley F.J., Brown A., Conroy D.M., Sabroe I., Pritchard D.I., Williams T.J. Eotaxin is specifically cleaved by hookworm metalloproteases preventing its action in vitro and in vivo. J. Immunol. 2000, 165:6447-6453.
101. Mejri N., Gottstein B. Echinococcus multilocularis metacestode metabolites contain a cysteine protease that digests eotaxin, a CC pro-inflammatory chemokine. Parasitol. Res. 2009, 105:1253-1260.
102. Proost P., Menten P., Struyf S., Schutyser E., De Meester I., Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000, 96:1674-1680.
103. Struyf S., Menten P., Lenaerts J.P., Put W., D'Haese A., De Clercq E., Schols D., Proost P., Van Damme J. Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. Eur. J. Immunol. 2001, 31:2170-2178.
104. Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen R.R., Xu H., Schilling A.B., Weber C., Ye R.D., Dinner A.R., Tang W.J. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. 2010, 29:3952-3966.
105. Quintero P.A., Knolle M.D., Cala L.F., Zhuang Y., Owen C.A. Matrix metalloproteinase-8 inactivates macrophage inflammatory protein-1 alpha to reduce acute lung inflammation and injury in mice. J. Immunol. 2010, 184:1575-1588.
106. Proost P., De Meester I., Schols D., Struyf S., Lambeir A.M., Wuyts A., Opdenakker G., De Clercq E., Scharpé S., Van Damme J. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J. Biol. Chem. 1998, 273:7222-7227.
107. Schols D., Proost P., Struyf S., Wuyts A., De Meester I., Scharpe S., Van Damme J., De Clercq E. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res. 1998, 39:175-187.
108. Struyf S., De Meester I., Scharpé S., Lenaerts J.P., Menten P., Wang J.M., Proost P., Van Damme J. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. 1998, 28:1262-1271.
109. Neote K., DiGregorio D., Mak J.Y., Horuk R., Schall T.J. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 1993, 72:415-425.
110. Berahovich R.D., Miao Z., Wang Y., Premack B., Howard M.C., Schall T.J. Proteolytic activation of alternative CCR1 ligands in inflammation. J. Immunol. 2005, 174:7341-7351.
111. Detheux M., Standker L., Vakili J., Munch J., Forssmann U., Adermann K., Pohlmann S., Vassart G., Kirchhoff F., Parmentier M., Forssmann W.G. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J. Exp. Med. 2000, 192:1501-1508.
112. Richter R., Casarosa P., Standker L., Munch J., Springael J.Y., Nijmeijer S., Forssmann W.G., Vischer H.F., Vakili J., Detheux M., Parmentier M., Leurs R., Smit M.J. Significance of N-terminal proteolysis of CCL14a to activity on the chemokine receptors CCR1 and CCR5 and the human cytomegalovirus-encoded chemokine receptor US28. J. Immunol. 2009, 183:1229-1237.
113. Ludwig A., Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb. Haemost. 2007, 97:694-703.
114. Abel S., Hundhausen C., Mentlein R., Schulte A., Berkhout T.A., Broadway N., Hartmann D., Sedlacek R., Dietrich S., Muetze B., Schuster B., Kallen K.J., Saftig P., Rose-John S., Ludwig A. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J. Immunol. 2004, 172:6362-6372.
115. Gough P.J., Garton K.J., Wille P.T., Rychlewski M., Dempsey P.J., Raines E.W. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J. Immunol. 2004, 172:3678-3685.
116. Hundhausen C., Schulte A., Schulz B., Andrzejewski M.G., Schwarz N., von Hundelshausen P., Winter U., Paliga K., Reiss K., Saftig P., Weber C., Ludwig A. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J. Immunol. 2007, 178:8064-8072.
117. Kageyama Y., Torikai E., Nagano A. Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol. Int. 2007, 27:467-472.
118. le Blanc L.M., van Lieshout A.W., Adema G.J., van Riel P.L., Verbeek M.M., Radstake T.R. CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement. Neurosci. Lett. 2006, 397:145-148.
119. Smith C., Halvorsen B., Otterdal K., Waehre T., Yndestad A., Fevang B., Sandberg W.J., Breland U.M., Froland S.S., Oie E., Gullestad L., Damas J.K., Aukrust P. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc. Res. 2008, 79:195-203.
120. Sun Y., Chang Z., Zhang S. Increased serum CXCL16 level is a marker for acute coronary syndromes. Arch. Med. Res. 2008, 39:332-337.
121. Deng L., Chen N., Li Y., Zheng H., Lei Q. CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim. Biophys. Acta 2010, 1806:42-49.
122. J. Meijer, J. Ogink, B. Kreike, D. Nuyten, K.E. de Visser, E. Roos, The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation, Cancer Res. 2008. Jun. 15. ;68. (12.):4701. -8. 68 (2008) 4701-4708.
123. Andrzejewski M.G., Koelsch A., Kogel T., Dreymueller D., Schwarz N., Ludwig A. Distinct role of the intracellular C-terminus for subcellular expression, shedding and function of the murine transmembrane chemokine CX3CL1. Biochem. Biophys. Res. Commun. 2010, 395:178-184.
124. Huang Y.W., Su P., Liu G.Y., Crow M.R., Chaukos D., Yan H., Robinson L.A. Constitutive endocytosis of the chemokine CX3CL1 prevents its degradation by cell surface metalloproteases. J. Biol. Chem. 2009, 284:29644-29653.
125. Garton K.J., Gough P.J., Blobel C.P., Murphy G., Greaves D.R., Dempsey P.J., Raines E.W. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 2001, 276:37993-38001.
126. Hundhausen C., Misztela D., Berkhout T.A., Broadway N., Saftig P., Reiss K., Hartmann D., Fahrenholz F., Postina R., Matthews V., Kallen K.J., Rose-John S., Ludwig A. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003, 102:1186-1195.
127. Chapman G.A., Moores K., Harrison D., Campbell C.A., Stewart B.R., Strijbos P.J. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J. Neurosci. 2000, 20:RC87.
128. Hatori K., Nagai A., Heisel R., Ryu J.K., Kim S.U. Fractalkine and fractalkine receptors in human neurons and glial cells. J. Neurosci. Res. 2002, 69:418-426.
129. Bourd-Boittin K., Basset L., Bonnier D., L'helgoualc'h A., Samson M., Theret N. CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J. Cell. Mol. Med. 2009, 13:1526-1535.
130. Truman L.A., Ford C.A., Pasikowska M., Pound J.D., Wilkinson S.J., Dumitriu I.E., Melville L., Melrose L.A., Ogden C.A., Nibbs R., Graham G., Combadiere C., Gregory C.D. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 2008, 112:5026-5036.
131. Jiang Y., Valente A.J., Williamson M.J., Zhang L., Graves D.T. Post-translational modification of a monocyte-specific chemoattractant synthesized by glioma, osteosarcoma, and vascular smooth muscle cells. J. Biol. Chem. 1990, 265:18318-18321.
132. Proost P., Mahieu F., Schutyser E., Van Damme J. Posttranslational processing of chemokines. Methods Mol. Biol. 2004, 239:27-44.
133. Needham M., Barratt D., Cerillo G., Green I., Warburton H., Anderson M., Sturgess N., Rollins B., Reilly C., Hollis M. High level expression of human MCP-1 using the LCR/MEL expression system. Protein Expr. Purif. 1996, 7:173-182.
134. Ruggiero P., Flati S., Cioccio Di V., Maurizi G., Macchia G., Facchin A., Anacardio R., Maras A., Lucarelli M., Boraschi D. Glycosylation enhances functional stability of the chemotactic cytokine CCL2. Eur. Cytokine Netw. 2003, 14:91-96.
135. Van Damme J., Decock B., Bertini R., Conings R., Lenaerts J.P., Put W., Opdenakker G., Mantovani A. Production and identification of natural monocyte chemotactic protein from virally infected murine fibroblasts. Relationship with the product of the mouse competence (JE) gene. Eur. J. Biochem. 1991, 199:223-229.
136. Luo Y., Laning J., Hayashi M., Hancock P.R., Rollins B., Dorf M.E. Serologic analysis of the mouse beta chemokine JE/monocyte chemoattractant protein-1. J. Immunol. 1994, 153:3708-3716.
137. Ernst C.A., Zhang Y.J., Hancock P.R., Rutledge B.J., Corless C.L., Rollins B.J. Biochemical and biologic characterization of murine monocyte chemoattractant protein-1. Identification of two functional domains. J. Immunol. 1994, 152:3541-3549.
138. Van Damme J., Proost P., Lenaerts J.P., Opdenakker G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J. Exp. Med. 1992, 176:59-65.
139. Minty A., Chalon P., Guillemot J.C., Kaghad M., Liauzun P., Magazin M., Miloux B., Minty C., Ramond P., Vita N. Molecular cloning of the MCP-3 chemokine gene and regulation of its expression. Eur. Cytokine Netw. 1993, 4:99-110.
140. Kameyoshi Y., Dorschner A., Mallet A.I., Christophers E., Schroder J.M. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J. Exp. Med. 1992, 176:587-592.
141. Oran P.E., Sherma N.D., Borges C.R., Jarvis J.W., Nelson R.W. Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin. Chem. 2010, 56:1432-1441.
142. Teixeira M.M., Wells T.N., Lukacs N.W., Proudfoot A.E., Kunkel S.L., Williams T.J., Hellewell P.G. Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J. Clin. Invest. 1997, 100:1657-1666.
143. Meurer R., Van Riper G., Feeney W., Cunningham P., Hora D., Springer M.S., MacIntyre D.E., Rosen H. Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8. J. Exp. Med. 1993, 178:1913-1921.
144. Richter R., Schulz-Knappe P., John H., Forssmann W.G. Posttranslationally processed forms of the human chemokine HCC-1. Biochemistry 2000, 39:10799-10805.
145. Dorner B., Muller S., Entschladen F., Schroder J.M., Franke P., Kraft R., Friedl P., Clark-Lewis I., Kroczek R.A. Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8(+) T cells. J. Biol. Chem. 1997, 272:8817-8823.
146. Marcaurelle L.A., Mizoue L.S., Wilken J., Oldham L., Kent S.B., Handel T.M., Bertozzi C.R. Chemical synthesis of lymphotactin: a glycosylated chemokine with a C-terminal mucin-like domain. Chemistry 2001, 7:1129-1132.
147. Dong C., Chua A., Ganguly B., Krensky A.M., Clayberger C. Glycosylated recombinant human XCL1/lymphotactin exhibits enhanced biologic activity. J. Immunol. Methods 2005, 302:136-144.
148. Hermand P., Pincet F., Carvalho S., Ansanay H., Trinquet E., Daoudi M., Combadiere C., Deterre P. Functional adhesiveness of the CX3CL1 chemokine requires its aggregation. Role of the transmembrane domain. J. Biol. Chem. 2008, 283:30225-30234.
149. Durkan A.M., Alexander R.T., Liu G.Y., Rui M., Femia G., Robinson L.A. Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells. J. Am. Soc. Nephrol. 2007, 18:74-83.
150. Vossenaar E.R., Zendman A.J., van Venrooij W.J., Pruijn G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25:1106-1118.
151. Moscarello M.A., Mastronardi F.G., Wood D.D. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 2007, 32:251-256.
152. Uysal H., Nandakumar K.S., Kessel C., Haag S., Carlsen S., Burkhardt H., Holmdahl R. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol. Rev. 2010, 233:9-33.
153. Pruijn G.J., Wiik A., van Venrooij W.J. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res. Ther. 2010, 12:203.
154. Loos T., Opdenakker G., Van Damme J., Proost P. Citrullination of CXCL8 increases this chemokine's ability to mobilize neutrophils into the blood circulation. Haematologica 2009, 94:1346-1353.
155. Struyf S., Noppen S., Loos T., Mortier A., Gouwy M., Verbeke H., Huskens D., Luangsay S., Parmentier M., Geboes K., Schols D., Van Damme J., Proost P. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J. Immunol. 2009, 182:666-674.